These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 24727841

  • 1. Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
    Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg JE, Chiche L, Hachulla E, Hatron PY, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Pers JO, Nowak E, Saraux A.
    Ann Intern Med; 2014 Feb 18; 160(4):233-42. PubMed ID: 24727841
    [Abstract] [Full Text] [Related]

  • 2. Summaries for patients. Does rituximab help patients with primary Sjögren syndrome?
    Ann Intern Med; 2014 Feb 18; 160(4):I-11. PubMed ID: 25006621
    [No Abstract] [Full Text] [Related]

  • 3. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial.
    Gottenberg JE, Ravaud P, Puéchal X, Le Guern V, Sibilia J, Goeb V, Larroche C, Dubost JJ, Rist S, Saraux A, Devauchelle-Pensec V, Morel J, Hayem G, Hatron P, Perdriger A, Sene D, Zarnitsky C, Batouche D, Furlan V, Benessiano J, Perrodeau E, Seror R, Mariette X.
    JAMA; 2014 Jul 16; 312(3):249-58. PubMed ID: 25027140
    [Abstract] [Full Text] [Related]

  • 4. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.
    Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, Emery P.
    Ann Rheum Dis; 2008 Nov 16; 67(11):1541-4. PubMed ID: 18276741
    [Abstract] [Full Text] [Related]

  • 5. Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjögren's Syndrome.
    Jousse-Joulin S, Devauchelle-Pensec V, Cornec D, Marhadour T, Bressollette L, Gestin S, Pers JO, Nowak E, Saraux A.
    Arthritis Rheumatol; 2015 Jun 16; 67(6):1623-8. PubMed ID: 25708147
    [Abstract] [Full Text] [Related]

  • 6. Effects of rituximab therapy on quality of life in patients with primary Sjögren's syndrome.
    Devauchelle-Pensec V, Morvan J, Rat AC, Jousse-Joulin S, Pennec Y, Pers JO, Jamin C, Renaudineau Y, Quintin-Roué I, Cochener B, Youinou P, Saraux A.
    Clin Exp Rheumatol; 2011 Jun 16; 29(1):6-12. PubMed ID: 21345287
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
    Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, Brouwer E, Kallenberg CG, Bootsma H.
    Arthritis Rheum; 2010 Apr 16; 62(4):960-8. PubMed ID: 20131246
    [Abstract] [Full Text] [Related]

  • 8. Does rituximab help patients with primary Sjögren syndrome?
    Ann Intern Med; 2014 Feb 18; 160(4):I-11. PubMed ID: 24727838
    [No Abstract] [Full Text] [Related]

  • 9. The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's Syndrome.
    Brown S, Navarro Coy N, Pitzalis C, Emery P, Pavitt S, Gray J, Hulme C, Hall F, Busch R, Smith P, Dawson L, Bombardieri M, Wan-Fai N, Pease C, Price E, Sutcliffe N, Woods C, Ruddock S, Everett C, Reynolds C, Skinner E, Poveda-Gallego A, Rout J, Macleod I, Rauz S, Bowman S, TRACTISS trial team.
    BMC Musculoskelet Disord; 2014 Jan 17; 15():21. PubMed ID: 24438039
    [Abstract] [Full Text] [Related]

  • 10. Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.
    Cornec D, Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg JE, Chiche L, Hachulla E, Hatron PY, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Seror R, Pers JO, Meiners PM, Vissink A, Bootsma H, Nowak E, Saraux A.
    Rheumatology (Oxford); 2015 Sep 17; 54(9):1699-708. PubMed ID: 25957440
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
    Gottenberg JE, Cinquetti G, Larroche C, Combe B, Hachulla E, Meyer O, Pertuiset E, Kaplanski G, Chiche L, Berthelot JM, Gombert B, Goupille P, Marcelli C, Feuillet S, Leone J, Sibilia J, Zarnitsky C, Carli P, Rist S, Gaudin P, Salliot C, Piperno M, Deplas A, Breban M, Lequerre T, Richette P, Ghiringhelli C, Hamidou M, Ravaud P, Mariette X, Club Rhumatismes et Inflammations and the French Society of Rheumatology.
    Ann Rheum Dis; 2013 Jun 17; 72(6):1026-31. PubMed ID: 23264337
    [Abstract] [Full Text] [Related]

  • 12. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM, Arends S, Brouwer E, Spijkervet FK, Vissink A, Bootsma H.
    Ann Rheum Dis; 2012 Aug 17; 71(8):1297-302. PubMed ID: 22258489
    [Abstract] [Full Text] [Related]

  • 13. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
    Liu X, Li X, Li X, Li Z, Zhao D, Liu S, Zhang M, Zhang F, Zhu P, Chen J, Wei W, Lin B, Zhou Y, Chen J, Pang Y, Zhang L, Sun X, Yu Z, Jia Y, Wang J, Sun W, Chiu F, Pang L, Wang G.
    Clin Rheumatol; 2019 Mar 17; 38(3):657-664. PubMed ID: 30280368
    [Abstract] [Full Text] [Related]

  • 14. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.
    Bowman SJ, Everett CC, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, Pease CT, Price EJ, Sutcliffe N, Gendi NST, Hall FC, Ruddock SP, Fernandez C, Reynolds C, Hulme CT, Davies KA, Edwards CJ, Lanyon PC, Moots RJ, Roussou E, Giles IP, Sharples LD, Bombardieri M.
    Arthritis Rheumatol; 2017 Jul 17; 69(7):1440-1450. PubMed ID: 28296257
    [Abstract] [Full Text] [Related]

  • 15. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20).
    Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, Roudaut A, Jamin C, Renaudineau Y, Roué IQ, Cochener B, Youinou P, Saraux A.
    Arthritis Rheum; 2007 Mar 15; 57(2):310-7. PubMed ID: 17330280
    [Abstract] [Full Text] [Related]

  • 16. Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.
    St Clair EW, Levesque MC, Prak ET, Vivino FB, Alappatt CJ, Spychala ME, Wedgwood J, McNamara J, Moser Sivils KL, Fisher L, Cohen P, Autoimmunity Centers of Excellence.
    Arthritis Rheum; 2013 Apr 15; 65(4):1097-106. PubMed ID: 23334994
    [Abstract] [Full Text] [Related]

  • 17. Treatment of primary Sjögren syndrome with rituximab.
    Faustman DL, Vivino FB, Carsons SE.
    Ann Intern Med; 2014 Sep 02; 161(5):376-7. PubMed ID: 25178574
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of primary Sjögren syndrome with rituximab. In response.
    Saraux A, Nowak E, Devauchelle-Pensec V.
    Ann Intern Med; 2014 Sep 02; 161(5):377-8. PubMed ID: 25178575
    [No Abstract] [Full Text] [Related]

  • 19. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.
    Hamza N, Bootsma H, Yuvaraj S, Spijkervet FK, Haacke EA, Pollard RP, Visser A, Vissink A, Kallenberg CG, Kroese FG, Bos NA.
    Ann Rheum Dis; 2012 Nov 02; 71(11):1881-7. PubMed ID: 22615459
    [Abstract] [Full Text] [Related]

  • 20. The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.
    Saraux A.
    Autoimmun Rev; 2010 Jul 02; 9(9):609-14. PubMed ID: 20452466
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.